Abstract
Sarcomas are the mesenchymal-derived malignant tumors of connective tissues (e.g., fat, bone, and cartilage) presumed to arise from aberrant development or differentiation of mesenchymal stem cells (MSCs). Appropriate control of stem cell maintenance versus differentiation allows for normal connective tissue development. Current theories suggest that loss of this control-through accumulation of genetic lesions in MSCs at various points in the differentiation process -leads to development of sarcomas, including undifferentiated, high grade sarcoma tumors [1]. The initiation of stem cell differentiation is highly associated with alteration of gene expression, which depends on chromatin remodeling [2, 3]. Epigenetic chromatin modifying agents have been shown to induce cancer cell differentiation and are currently being used clinically to treat cancer. This review will focus on the importance of epigenetic chromatin remodeling in the context of mesenchymal stem cells, sarcoma tumorigenesis and differentiation therapy.
Keywords: Mesenchymal stem cell, sarcoma, differentiation, histone deacetylase inhibitor, chromatin
Current Stem Cell Research & Therapy
Title: Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Volume: 5 Issue: 1
Author(s): Sara Siddiqi, Joslyn Mills and Igor Matushansky
Affiliation:
Keywords: Mesenchymal stem cell, sarcoma, differentiation, histone deacetylase inhibitor, chromatin
Abstract: Sarcomas are the mesenchymal-derived malignant tumors of connective tissues (e.g., fat, bone, and cartilage) presumed to arise from aberrant development or differentiation of mesenchymal stem cells (MSCs). Appropriate control of stem cell maintenance versus differentiation allows for normal connective tissue development. Current theories suggest that loss of this control-through accumulation of genetic lesions in MSCs at various points in the differentiation process -leads to development of sarcomas, including undifferentiated, high grade sarcoma tumors [1]. The initiation of stem cell differentiation is highly associated with alteration of gene expression, which depends on chromatin remodeling [2, 3]. Epigenetic chromatin modifying agents have been shown to induce cancer cell differentiation and are currently being used clinically to treat cancer. This review will focus on the importance of epigenetic chromatin remodeling in the context of mesenchymal stem cells, sarcoma tumorigenesis and differentiation therapy.
Export Options
About this article
Cite this article as:
Siddiqi Sara, Mills Joslyn and Matushansky Igor, Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas, Current Stem Cell Research & Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/157488810790442859
DOI https://dx.doi.org/10.2174/157488810790442859 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Recent Advances in Luminescent Carbon Dots
Current Analytical Chemistry Cashew Gum A Versatile Hydrophyllic Polymer: A Review
Current Drug Therapy Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight
Recent Patents on Biotechnology Outcome Measures Following Sonodynamic Photodynamic Therapy – A Case Series
Current Drug Therapy Copper(II) Complexes with Saccharinate and Glutamine as Antitumor Agents: Cytoand Genotoxicity in Human Osteosarcoma Cells
Anti-Cancer Agents in Medicinal Chemistry Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer
Current Pharmaceutical Design The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Induction of Abscopal Anti-Tumor Immunity and Immunogenic Tumor Cell Death by Ionizing Irradiation - Implications for Cancer Therapies
Current Medicinal Chemistry Particle-based Vaccines for HIV-1 Infection
Current Drug Targets - Infectious Disorders Effectiveness of Two Novel Anionic and Cationic Platinum Complexes in the Treatment of Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Current Topics in Medicinal Chemistry Murabutide Revisited: A Review of its Pleiotropic Biological Effects
Current Medicinal Chemistry The Targets of Curcumin
Current Drug Targets Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets